Combining CLS-015 with CAR-T for large B-cell lymphoma
Part of Cancer clinical trials.
This trial tests combining an experimental drug (CLS-015) with a standard CAR-T cell therapy for people with large B-cell lymphoma whose disease is stable or progressing. It aims to see if the combination is safe and might improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have large B-cell lymphoma and have already received CAR-T cell therapy (like Kymriah, Yescarta, or Breyanzi).
- Your lymphoma must be stable or growing (not getting better) at the time your doctor gives you the pre-CAR-T chemotherapy.
- You must be able to take care of yourself and not need bed rest most of the day (ECOG 0 to 2).
- You must not be allergic to the study drug CLS-015.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy designed to target and destroy cancer cells that have the CD19 marker. It may help people with large B-cell lymphoma that has relapsed or not responded to standard treatments.
This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.
This study tests a customized cancer treatment called CD19 CAR-T for people newly diagnosed with certain high-risk large B-cell lymphoma. It aims to see whether this treatment can help control the lymphoma, especially in higher-risk cases.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two treatments—CAR T-cells (your own immune cells reprogrammed to attack cancer) and lenalidomide (a pill that boosts the immune system)—for people with chronic lymphocytic leukemia (CLL) that has not responded to or returned after at least one prior treatment. It aims to see if this combination is safe and works better than either alone.
Hear when a new Large B-Cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.